Eli Lilly, Boehringer Ingelheim Get FDA OK for Jardiance in Chronic Kidney Disease
22 Setembro 2023 - 10:19AM
Dow Jones News
By Colin Kellaher
Eli Lilly and Boehringer Ingelheim have won expanded U.S. Food
and Drug Administration approval of their blockbuster diabetes drug
Jardiance for certain adults with chronic kidney disease.
The companies on Friday said the approval covers Jardiance to
reduce the risk of sustained decline in estimated glomerular
filtration rate, end-stage kidney disease, cardiovascular death and
hospitalization in adults with chronic kidney disease at risk of
progression.
Indianapolis drug maker Eli Lilly and Boehringer Ingelheim, a
family-owned pharmaceutical company based in Ingelheim, Germany,
jointly market Jardiance as part of a 2011 alliance.
The FDA first approved Jardiance in 2014 for adults with type 2
diabetes and later approved the drug to reduce the risk of
cardiovascular death in adults with type 2 diabetes and established
cardiovascular disease, and to reduce the risk of death and
hospitalization in adults with heart failure.
Eli Lilly reported Jardiance revenue of nearly $1.25 billion for
the first six months of the year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 22, 2023 09:04 ET (13:04 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Gráfico Histórico do Ativo
De Nov 2023 até Dez 2023
Eli Lilly (NYSE:LLY)
Gráfico Histórico do Ativo
De Dez 2022 até Dez 2023
